Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1972 1
1978 1
1986 1
1990 1
2001 1
2002 3
2003 5
2004 6
2005 5
2006 5
2007 7
2008 8
2009 16
2010 13
2011 13
2012 19
2013 21
2014 9
2015 12
2016 5
2017 5
2018 6
2019 22
2020 11
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

179 results
Results by year
Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Onoi K, et al. Among authors: chihara y. J Clin Med. 2020 May 6;9(5):1362. doi: 10.3390/jcm9051362. J Clin Med. 2020. PMID: 32384677 Free PMC article. Review.
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Sakakida T, et al. Among authors: chihara y. Clin Transl Oncol. 2020 Jun;22(6):919-927. doi: 10.1007/s12094-019-02214-8. Epub 2019 Oct 1. Clin Transl Oncol. 2020. PMID: 31576495
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K. Hiranuma O, et al. Among authors: chihara y. Clin Lung Cancer. 2019 May;20(3):e402-e406. doi: 10.1016/j.cllc.2019.02.016. Epub 2019 Feb 27. Clin Lung Cancer. 2019. PMID: 30905617 Free article. Clinical Trial.
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. Yamada T, et al. Among authors: chihara y. Cancer Med. 2019 Apr;8(4):1521-1529. doi: 10.1002/cam4.2037. Epub 2019 Feb 21. Cancer Med. 2019. PMID: 30790471 Free PMC article.
Tumor Neovascularization and Developments in Therapeutics.
Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Katayama Y, et al. Among authors: chihara y. Cancers (Basel). 2019 Mar 6;11(3):316. doi: 10.3390/cancers11030316. Cancers (Basel). 2019. PMID: 30845711 Free PMC article. Review.
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Katayama Y, Yamada T, Chihara Y, Tanaka S, Tanimura K, Okura N, Hirose K, Uda S, Shiotsu S, Hirai S, Hiranuma O, Harada T, Shimamoto T, Iwasaku M, Kaneko Y, Uchino J, Takeda T, Takayama K. Katayama Y, et al. Among authors: chihara y. Sci Rep. 2020 Oct 15;10(1):17495. doi: 10.1038/s41598-020-74573-0. Sci Rep. 2020. PMID: 33060826 Free PMC article.
179 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page